The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: Dalpiciclib in combination with endocrine therapy by Physicians choice
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: Jiangsu HengRui Medicine Co., Ltd.